How many hours before a left‑heart catheterization should therapeutic enoxaparin (Lovenox) 65 mg be held?

Hold Lovenox 24 Hours Before Left Heart Catheterization

For therapeutic enoxaparin (Lovenox) 65 mg, hold the medication 24 hours before left heart catheterization. This timing ensures adequate clearance of anticoagulant effect while minimizing bleeding risk during the procedure.

Rationale and Timing

The 24-hour hold period is based on established guidelines for managing low-molecular-weight heparin (LMWH) before invasive procedures. The most recent ACC/AHA guidelines 1 and ASCO cancer anticoagulation guidelines 2 specify that therapeutic LMWH doses should not be administered within 24 hours before neuraxial procedures or catheter manipulation. While left heart catheterization is not a neuraxial procedure, the same bleeding risk principles apply for arterial access procedures.

Key Considerations:

• Last dose timing: If the patient takes enoxaparin twice daily (every 12 hours), skip both the evening dose before and morning dose of the procedure day
• Once daily dosing: If dosed once daily, ensure 24 hours have elapsed since the last dose
• Renal function: The 65 mg dose suggests this may be a renally-adjusted regimen (standard therapeutic dosing is typically 1 mg/kg every 12 hours or 1.5 mg/kg once daily). Patients with renal impairment may have prolonged drug clearance, making the 24-hour window even more critical

Procedural Anticoagulation Management

When the patient arrives for catheterization after holding enoxaparin:

• Do not administer additional enoxaparin if the last dose was >12 hours ago 1
• Use unfractionated heparin (UFH) during the procedure as needed to support PCI, with dosing adjusted to achieve ACT 250-300 seconds 1
• Avoid switching back and forth between enoxaparin and UFH, as this increases bleeding risk 3

Post-Procedure Resumption

After uncomplicated left heart catheterization:

• Resume enoxaparin 24-48 hours post-procedure for low-to-moderate bleeding risk procedures 4
• For high bleeding risk or if complications occurred, wait 48-72 hours before resuming therapeutic anticoagulation 4
• Consider bridging with prophylactic-dose LMWH (enoxaparin 40 mg daily) for the first 24-72 hours if VTE risk is high, then resume full therapeutic dosing 2, 4

Common Pitfalls to Avoid

1. Don't give "booster" doses: If enoxaparin was held appropriately for 24 hours, additional anticoagulation during the procedure should be UFH only, not supplemental enoxaparin
2. Don't resume too early: Premature resumption of therapeutic anticoagulation increases access site bleeding and retroperitoneal hematoma risk
3. Check renal function: The 65 mg dose may indicate CrCl 15-30 mL/min; verify this hasn't worsened with contrast exposure before resuming

The 24-hour hold provides adequate safety margin for most patients while maintaining the option to use procedural UFH as needed 5, 1, 6.